Siemens Healthineers has announced the release of its new CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test.1,2
FTD SARS-CoV-2/FluA/FluB/HRSV combination PCR test
Validated on the company’s VERSANT kPCR Molecular System, the kit combines Siemens Healthineers FTD SARS-CoV-23 and FTD Flu/HRSV Assays.1 The new FTD SARS-CoV-2/FluA/FluB/HRSV Assay enables comprehensive and semi-automated molecular testing for seasonal respiratory pathogens. The combination PCR test detects and differentiates between clinically relevant viruses: SARS-CoV-2, Influenza A, Influenza B, and HRSV A/B. Preserving sensitivity via the separate detection of SARS-CoV-2 targets allows the company’s highly effective, proven FTD SARS-CoV-2 Assay to perform without any compromise to sensitivity, maintaining key features of the top-performing assay.
CLINITEST Rapid COVID-19 + Influenza A/B Antigen Test
This convenient 3-in-1 test, administered by a healthcare professional in virtually any medical setting, provides reliable results in 15 minutes. With no instrumentation or equipment required, a single nasopharyngeal swab sample can differentiate between SARS-CoV-2, Influenza A, and Influenza B infections. This test provides high sensitivity and specificity (98.32%/99.60% for SARS-CoV-2, 88.57%/97.78% for Flu A, and 87.10%/97.87% for Flu B). Results can facilitate prompt self-isolation of infected patients, if deemed necessary, to prevent the spread of SARS-CoV-2 and influenza.
“As we approach the high season for cold and flu viruses in the UK, with the additional presence of COVID-19, it’s imperative we enable healthcare professionals with the right tools to differentiate between these infections,” states Stewart Hutton, Head of Diagnostics, Siemens Healthineers GB&I. "With A&E and hospital settings under pressure, the CLINITEST Rapid COVID-19 + Influenza A/B Antigen Test from Siemens Healthineers provides results in 15 minutes, prompting timely management of viral infections and helping to reduce the spread of SARS-CoV-2 and seasonal respiratory viruses.”